Orca Bio

Orca Bio, a late-stage biotechnology company, has raised $192 million across multiple funding rounds, including a $192 million Series D in June 2020 led by Lightspeed Venture Partners. The company develops high-precision allogeneic T-cell therapies for cancer and autoimmune diseases, harnessing regulatory T cells to improve patient outcomes with fewer risks. Orca Bio’s investigational therapies, including TRGFT-201 and OGFT-001, aim to transform conventional bone marrow transplants. Supported by leading investors such as 8VC, DCVC Bio, and Mubadala Investment Company, Orca Bio is advancing clinical trials and expanding its therapeutic pipeline.